

VistaPlex™ Rapid Immune Profiling Assay Kit

CellScape™ Multiplexed Assay Kit for Human PBMC Samples AbKT-1004-10RXN

Overview

Description

VistaPlex Assay Kits contain ready-to-use, reliable reagents and optimized protocols enabling researchers to obtain quick, robust data with the CellScape platform. Designed to provide a convenient, flexible, and modular analysis of immune cells, the Rapid Immune Profiling Assay kit enables relative quantification of 10 phenotypic biomarkers that define T Cell, B Cell, Leukocytes, NK Cell, NKT Cell, Monocyte and Dendritic Cell populations and sub-populations in human PMBC samples. Immune cells can be characterized in 2 short staining cycles.


Each Rapid Immune Profiling Assay Kit contains 10 prevalidated fluorescent antibodies and buffers for staining 10 samples. This kit was validated on Fresh CPT PBMCs and has also been tested on Cyto-Chex® BCT-stored PBMCs and cryopreserved PBMCs. Multiplex assay kit validation is a multi-stage, iterative process to evaluate antibodies for suitability, specificity and reproducibility.

Report Contents

- Product Details
- Staining Protocol and Gating Strategy
- Assay Validation Process
- Representative Data

Data Summary

Sample Type	Suitability	Specificity	Reproducibility
Fresh CPT PBMCs	\checkmark	✓	✓
Cyto-Chex PBMCs	\checkmark	✓	✓
Cryopreserved PBMCs	✓	✓	✓



Human PMBCs were stained and imaged using the Rapid Immune Profiling Assay Kit. Select biomarkers for phenotyping immune cell populations are displayed.



Product Details

Kit Contents

Description	Volume	Cap Color	
Anti-HLA-DR Antibody	100 μL		
Anti-CD56 Antibody	100 μL		
Anti-CD11c Antibody	100 μL	Red	
Anti-CD4 Antibody	100 μL	-	
Anti-CD8 Antibody	100 μL		
Anti-CD123 Antibody	100 μL	_	
Anti-CD14 Antibody	100 μL	Orange	
Anti-CD20 Antibody	100 μL		
Anti-CD45 Antibody	100 μL		
Anti-CD3 Antibody	100 μL		
Antibody Diluent	50 mL	N/A	

Storage

Store assay kit components protected from light at 2-8 °C.

Shelf Life

9 months from date received.

Fixation Conditions

Fixation is performed by incubating samples in CellScape Fixation Buffer for 45 minutes at 4 °C.

System Compatibility

The Rapid Immune Profiling Assay Kit has been optimized for use with the CellScape platform. CellScape supports image exports in OME-tiff and png formats for use in any analysis software.

Intended Use

Research Use Only, not for use in diagnostic procedures. Intended for human PBMCs.



Staining Protocol

Panel Set Up

The staining protocol for the Rapid Immune Profiling Assay Kit is accomplished in two cycles. A single antibody working stock is created for each cycle, following the dilution instructions in the table below. To customize your panel, add additional cycles using pre-validated antibodies from our biomarker catalog or supplement with fluorescently labeled antibodies from your own inventory.

The Rapid Immune Profiling Assay Kit has been optimized to maximize throughput by minimizing the

number of cycles required for analysis. Additional cycles may be added for further customization of your high-plex assay.

Imaging

The CellScape's high dynamic range (HDR) imaging technology collects images across a series of exposure times to capture the full range of fluorescence values of each stain, including low-expression biomarkers. Each marker is imaged individually and then overlayed by aligning each channel to a reference channel.

Cycle	Target	Filter Set	Antibody Volume	Diluent Volume	Incubation Time
1	HLA-DR	FSPerCP	10 μL	- _ 250 μL	5 min
	CD56	FS560	10 μL		
	CD11c	FS488	10 μL		
	CD4	FS421	10 μL		
	CD8	FS395	10 μL		
2	CD123	FSPerCP	10 μL	_	5 min
	CD14	FS560	10 μL	250 μL	
	CD20	FS488	10 μL		
	CD45	FS421	10 μL		
	CD3	FS395	10 μL		



Example Gating Strategy

Cell Population	Parent Gate	Gating Strategy
Leukocytes	All	CD45+
T cells	Leukocytes	CD45+ CD3+ CD56-
NK cells	Leukocytes	CD45+ CD3- CD56+
NKT cells	Leukocytes	CD45+ CD3+ CD56+
T cytotoxic cells	T cells	CD45+ CD3+ CD56- CD4- CD8+
T helper cells	T cells	CD45+ CD3+ CD56- CD4+ CD8-
B cells	Leukocytes	CD45+ CD3- CD56- CD20+ CD14-
Monocytes	Leukocytes	CD45+ CD3- CD56- CD20- CD14+
Dendritic cells	Leukocytes	CD45+ CD3- CD56- CD20- CD14- HLA-DR+
Myeloid Dendritic cells	Dendritic cells	CD45+ CD3- CD56- CD20- CD14- HLA-DR+ CD11c+ CD123-
Plasmacytoid Dendritic cells	Dendritic cells	CD45+ CD3- CD56- CD20- CD14- HLA-DR+ CD11c- CD123+

Gating Details


The Rapid Immune Profiling Assay Kit enables spatial phenotyping of key immune populations including those listed in the table above. Additional phenotypes can be identified for different degrees of expression of single markers.

Gating Plots

Shown on page 5 are representative bivariate plots of fluorescence intensity, demonstrating a hierarchical gating strategy to characterize and quantify immune cells in PBMC samples using the Rapid Immune Profiling Assay Kit.



Example Gating Strategy (continued)





Assay Validation Process

Antibodies in the Rapid Immune Profiling Assay Kit have been fully validated for precise and consistent performance in human PBMC suspensions.

Specificity

All assay kit antibodies undergo rigorous testing to ensure antibodies bind their intended targets and do not demonstrate off-target effects. The specificity of each antibody is assessed with appropriate counterstains to ensure that antibodies stain their intended cell types and localize to the expected subcellular regions. The table below lists the expected localization of the biomarker targets in this kit and the antibodies that passed the requirements for staining localization and specificity. A representative composite stain image is shown on page 1.

Reproducibility

The Rapid Immune Profiling Assay Kit was tested on technical replicates from three different donors. Fresh PMBC samples were used to confirm intra-assay and inter-assay reproducibility. To ensure high quality data can be obtained on a variety of sample types, the assay kit was successfully tested on fresh, cryopreserved, and Cyto-Chex BCT-collected samples. Immune cell populations were quantified using the example gating strategy on page 4 and compared across replicates.

Data Analysis

Data analysis was performed in the ZKW Data Wizard application. Cells were identified by computational segmentation on nuclear stain images. Staining data were reviewed independently by two analysts.

Individual Antibody Validation Results


Marker	Visible Signal	Subcellular Localization	Specific Localized Signal	Review by 2 Analysts
HLA-DR	Pass	Surface	Pass	Pass
CD56	Pass	Surface	Pass	Pass
CD11c	Pass	Surface	Pass	Pass
CD4	Pass	Surface	Pass	Pass
CD8	Pass	Surface	Pass	Pass
CD123	Pass	Surface	Pass	Pass
CD14	Pass	Surface	Pass	Pass
CD20	Pass	Surface	Pass	Pass
CD45	Pass	Surface	Pass	Pass
CD3	Pass	Surface	Pass	Pass



Representative Validation Data

Specificity

Shown are representative images for specificity assessment of four Rapid Immune Profiling Assay Kit antibodies. CD45 staining overlaps with both CD3 and CD20 as expected for immune cells. CD3 and CD20 antibodies stain non-overlapping cell populations as expected for T cells and B cells, respectively. CD14 staining is present on morphologically distinct myeloid cells and does not overlap with lymphocyte markers.







Representative Validation Data (continued)

Reproducibility

The Rapid Immune Profiling Assay Kit was demonstrated to produce reproducible and consistent results across samples storage types by assaying technical duplicates from different donors with three different sample storage methods. Leukocyte populations were quantified as percentage of parent population using the gating strategy shown on page 4. Shown below are quantitative cell phenotyping results from three different cryopreserved samples, with similar colors represent technical replicates from the same donor.






C

Representative Validation Data (continued)

Reproducibility (continued)



Technical Support

For additional questions or technical support in North America, contact support.canopy@bruker.com For additional questions or technical support in Europe, contact support.canopy.europe@bruker.com

Data and other information provided in this document are based on information, tests, or research that Canopy Biosciences considers reliable, but the accuracy or completeness of such information is not guaranteed. Such information is intended for persons with technical expertise and knowledge sufficient to assess and apply their own informed judgment. Canopy Biosciences shall not be liable for any technical or editorial errors.

To learn more, visit CanopyBiosciences.com

Canopy Biosciences 4340 Duncan Avenue Suite 220 Saint Louis, Missouri 63110

